NASDAQ:BDTX
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.'s revenue was $70.0M in fiscal 2025. The diluted share count rose 4.6%.Summary generated from Black Diamond Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$70.0M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin17.9%
Net margin32.0%
ROICn/a
Return on equity22.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+4.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 70 |
| Operating income | −127 | −93 | −86 | −79 | 13 |
| Net income | −126 | −91 | −82 | −70 | 22 |
| Free cash flow | −103 | −85 | −67 | −62 | n/a |
Recent filings
- 4Insider transaction report
Sep 21, 2026 - 4Insider transaction report
Sep 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KResults of a shareholder vote
Jun 29, 2026 - 8-KRegulation FD disclosure
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026